Post-earnings recap
Reported
Thu, Nov 2, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a strong earnings surprise with an EPS of $1.74, significantly above expectations. The stock reacted positively, rising 2.89% as investors responded to the strong performance in their pipeline. However, the lack of revenue figures and future guidance may leave some investors cautious.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.74 | N/A | +207.94% |
| Revenue | N/A | N/A | N/A |
Management conveyed a positive outlook regarding their product pipeline and ongoing trials. However, they did not offer specific guidance for future performance.
Management highlighted strong performance in their pipeline.
They expressed confidence in ongoing clinical trials.
No specific guidance was provided for future quarters.